# Andera Partners

Source: https://onco.cc/companies/andera-partners/  
OnCo record `andera-partners` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Paris private equity firm whose life sciences team, through its BioDiscovery funds, invests in European and US drug and medtech companies. Its life sciences portfolio includes the cancer T-cell therapy company T-Knife.

## Summary

Andera Partners describes itself as 'an asset management firm specialising in Private Equity' with '6 billion under management' and '377 companies supported in over 20 years'. Its andera Life Sciences team invests from preclinical through commercial stages in Europe and the US from offices in Paris and Munich, putting EUR 15 million to 60 million per company; the BioDiscovery fund series has run since 2004 with BioDiscovery 7 currently raising. The life sciences page names ReViral, Inotrem, T-Knife, Corvidia, Axonics and Poxel. Of these, T-Knife develops next-generation T-cell receptor therapies for cancer (its Series A is also listed in Versant Ventures' news). The others are antiviral, sepsis, cardiovascular, neuromodulation and metabolic companies.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Tags: vc
- HQ: Paris
- Type: investor
- Website: https://www.anderapartners.com/en/

## Notes

- Founding year of the firm not stated on fetched pages (it says 'over 20 years'); omitted. Only one oncology company could be confirmed.

## Sources

- Official website: https://www.anderapartners.com/en/
- Life sciences: https://www.anderapartners.com/en/expertise/life-sciences-biotechnologies/

## Connected records

- companies: [Nouscom](https://onco.cc/companies/nouscom/)

---
JSON: https://onco.cc/api/v1/entities/andera-partners.json